GlaxoSmithKline
Rick Caimi has nearly 20 years experience in the biopharmaceutical industry spanning virtual biotech organizations through large Pharma. In his current role as Director of Early Phase CMC Development, Rick is responsible for leading development activities supporting Pre-Clinical and Phase I/II manufacturing for all BioPharms in GSKs growing development pipeline. He received his Ph.D. in biochemistry from Cornell University in 1995.